Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

10175	Companies
209234	Keywords
139303	Articles
110894	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 4 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 4 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 4 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 4 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 4 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 4 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 4 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year 4 months ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year 4 months ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year 4 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform

Accesswire

Published on 04/08/2026 at 14:30, 40 minutes ago

Goldcliff Confirms Free Gold at Kettle Valley North Cliff Zone, Assays up to 2.70 g/t Au and 29.2 g/t Ag
Published on 04/08/2026 at 14:30, 40 minutes ago

Datametrex Enters Strategic Agreement with Hilco Global to Advance Patent Monetization
Published on 04/08/2026 at 14:30, 40 minutes ago

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published on 04/08/2026 at 14:22, 48 minutes ago

CBMJ Completes Patriot.TV Asset Sale, Reduces Capital Requirements and Accelerates Path Toward Contemplated Strategic Acquisition
Published on 04/08/2026 at 14:00, 1 hour 10 minutes ago

Horizon Aircraft and MHIRJ Join Forces to Advance Regional Air Mobility

View all ACCESSWIRE

EQS Group

Published on 04/08/2026 at 14:54, 15 minutes ago

MPC Capital: Invitation to the FY 2025 earnings webcast on 9 April 2026
Published on 04/08/2026 at 14:50, 19 minutes ago

SANY Reports 41% Increase in 2025 Net Profit; Operating Cash Flow Reaches $2.80 Billion
Published on 04/08/2026 at 14:48, 21 minutes ago

Moody’s downgrades Amprion’s credit rating to “Baa2” and revises outlook to “stable'
Published on 04/08/2026 at 14:05, 1 hour 4 minutes ago

Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
Published on 04/08/2026 at 14:05, 1 hour 4 minutes ago

Duck Creek Launches Duck Creek Reinsurance with Active Delivery to Help Insurers Simplify Program Management and Improve Financial Control

Les Echos

Published on 04/08/2026 at 12:58, 2 hours 11 minutes ago

EURAZEO SE VOIT ATTRIBUER LA NOTE DE CREDIT BBB (PERSPECTIVE STABLE) PAR S&P ET BBB (PERSPECTIVE STABLE) PAR FITCH.
Published on 04/08/2026 at 12:58, 2 hours 11 minutes ago

EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH
Published on 04/08/2026 at 11:50, 3 hours 19 minutes ago

Mise à disposition du Document d’Enregistrement Universel 2025, incluant le rapport financier annuel 2025
Published on 04/08/2026 at 11:00, 4 hours 10 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 04/08/2026 at 11:00, 4 hours 10 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL

View all LES ECHOS COMFI WIRE